Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
Overview | Financials
Company Name | Recursion Pharmaceuticals, Inc. |
Symbol | RXRX |
Currency | USD |
Price | 7.39 |
Market Cap | 2,835,712,970 |
Dividend Yield | 0% |
52-week-range | 5.6 - 15.74 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Christopher C. Gibson Ph.D. |
Website | https://www.recursion.com |
An error occurred while fetching data.
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD